Emmanuel Caeymaex is Executive Vice President, Immunology and U.S. Solutions at UCB, leading worldwide development and commercialization of innovative solutions that create unique value for people suffering from severe inflammatory and autoimmune disorders, such as psoriatic arthritis, axial spondyloarthritis, psoriasis, , rheumatoid arthritis, Crohn’s disease, and osteoporosis with ongoing research in hidradenitis suppurativa and systemic lupus erythematosus. He is also in charge of UCB’s corporate activities and operations in the United States and leads medical affairs and UCB’s digital business transformation initiative. 

Since joining UCB in 1994, Emmanuel has been instrumental in advancing UCB’s transformation into a global biopharma company focused on patients with severe diseases. Prior to this role he led the CIMZIA® (certolizumab pegol) Global Patient Solutions team. Emmanuel formerly served as President of UCB Japan Co Ltd. from September 2006 to June 2011 and on the Global Operations Committee. He previously contributed to build UCB’s leadership position in epilepsy, successively as Global Brand Manager KEPPRA® (levetiracetam), UK Business Unit Head, and Vice President Global Marketing for Central Nervous System products. Prior to 1999, Emmanuel established and ran UCB’s operations in several Asia-Pacific markets for which he was awarded as Laureate of the Prince Albert Fund where he has served as President since May 2019. He also currently serves on the board of the Biotechnology Innovation Organization (BIO). 

Emmanuel received a Business Engineer MSc degree from the University of Louvain, (Belgium), a Master’s in International Management from the Community of European Management Schools (and continued his executive leadership development journey at INSEAD. 


Download Bio